Trillium Therapeutics welcomes Paolo Pucci to its Board of Directors

– CANADA, Mississauga –  Trillium Therapeutics Inc. (TSX: TRIL | NASDAQ: TRIL), a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced the appointment of Paolo Pucci to its Board of Directors, effective immediately.

Mr. Pucci, a pharmaceutical industry leader has significant expertise in oncology drug development and decades of leadership experience across large and small organizations over his 30-year career.

“We are delighted to welcome Mr. Pucci to the board of directors” said Board Chair, Dr. Robert Kirkman. “His broad executive and commercial expertise, specifically in the field of oncology, will be invaluable as Trillium prepares for later stage clinical development.”

About Paolo Pucci

Most recently, Mr. Pucci served as CEO of the targeted therapeutics oncology company, ArQule, until it was acquired by Merck for $2.7 billion in January 2020. Before ArQule, Mr. Pucci served in several leadership positions at Bayer AG from 2001 to 2008, including President of the Oncology & Global Specialty Medicines Business Units, and was a member of the Bayer Pharmaceuticals Global Management Committee. Mr. Pucci also held multiple roles at Eli Lily and Company from 1991 to 2001.

“I look forward to contributing my knowledge in oncology drug development and commercialization over the coming years,” said Mr. Pucci. “There has never been a more exciting time to be developing novel oncology agents, and Trillium is well-positioned in the field.”

Mr. Pucci received his M.S. in economics and accounting from Università Degli Studi di Napoli Federico II and an MBA in marketing and finance from the University of Chicago. He currently serves as a board member of West Pharmaceuticals Services Inc., Merus N.V., and Replimune Inc., and had previous board roles at NewLink Genetics Inc., Dyax Inc., and Algeta ASA.

About Trillium Therapeutics

Trillium is an immuno-oncology company developing innovative therapies for the treatment of cancer. The company’s two clinical programs, TTI-621 and TTI-622, target CD47, a “don’t eat me” signal that cancer cells frequently use to evade the immune system.

For more information: https://trilliumtherapeutics.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team